Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Other literature type . 2026
License: CC BY
Data sources: ZENODO
ZENODO
Other literature type . 2026
License: CC BY
Data sources: Datacite
ZENODO
Other literature type . 2026
License: CC BY
Data sources: Datacite
 View all 2 versions
Claim

Perspectives and Insights on Immune Checkpoint Inhibitors (PD-1 and LAG-3 Monoclonal Antibodies) within Antineoplastic Immunomodulators (L01X): From Development to Submission of a New Drug Submission (NDS) in Canada

descriptionPublicationkeyboard_double_arrow_right Other literature type 22 Jan 2026Publisher:Crown College of Canada
Authors: Bhatti, Naila; Manjunath, Divya Bangalore; Yabaluri, Himaja; Jetty, Stella; Pirouzi, Peivand;

doi: 10.5281/zenodo.18332402 , 10.5281/zenodo.18332403

Perspectives and Insights on Immune Checkpoint Inhibitors (PD-1 and LAG-3 Monoclonal Antibodies) within Antineoplastic Immunomodulators (L01X): From Development to Submission of a New Drug Submission (NDS) in Canada

Abstract

Immune checkpoint inhibitors (ICIs) transformed oncology by redefining cancer therapy from cytotoxic suppression to immune system reactivation. The dual blockade of PD-1 and LAG-3 marks a pivotal advancement in immuno-oncology, offering enhanced antitumor activity through complementary immune-regulatory mechanisms. This review analyzes the L01X immune checkpoint inhibitor class, emphasizing pharmacologic profiles, structural characteristics, container-closure systems, and safety considerations of PD-1 and LAG-3 monoclonal antibody combinations.

Related Organizations
  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    		 Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    		 Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
Green
Related to Research communities
Cancer Research